<?xml version="1.0" encoding="UTF-8"?>
<TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink"
            xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
            xmlns="ted/R2.0.9.S02/publication"
            xmlns:n2016="ted/2016/nuts"
            xsi:schemaLocation="ted/R2.0.9.S02/publication TED_EXPORT.xsd"
            VERSION="R2.0.9.S02.E01"
            DOC_ID="019945-2018"
            EDITION="2018011">
   <TECHNICAL_SECTION>
      <RECEPTION_ID>18-017444-001</RECEPTION_ID>
      <DELETION_DATE>20180206</DELETION_DATE>
      <FORM_LG_LIST>DA DE EN ES FI FR EL IT NL PT SV CS ET HU LT LV MT PL SK SL GA BG RO HR </FORM_LG_LIST>
      <COMMENTS>From Convertor</COMMENTS>
   </TECHNICAL_SECTION>
   <LINKS_SECTION>
      <XML_SCHEMA_DEFINITION_LINK xlink:type="simple"
                                  xlink:href="http://ted.europa.eu"
                                  xlink:title="TED WEBSITE"/>
      <OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <FORMS_LABELS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
      <ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="http://ted.europa.eu"/>
   </LINKS_SECTION>
   <CODED_DATA_SECTION>
      <REF_OJS>
         <COLL_OJ>S</COLL_OJ>
         <NO_OJ>11</NO_OJ>
         <DATE_PUB>20180117</DATE_PUB>
      </REF_OJS>
      <NOTICE_DATA>
         <NO_DOC_OJS>2018/S 011-019945</NO_DOC_OJS>
         <URI_LIST>
            <URI_DOC LG="DA">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:DA:HTML</URI_DOC>
            <URI_DOC LG="DE">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:DE:HTML</URI_DOC>
            <URI_DOC LG="EN">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:EN:HTML</URI_DOC>
            <URI_DOC LG="ES">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:ES:HTML</URI_DOC>
            <URI_DOC LG="FI">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:FI:HTML</URI_DOC>
            <URI_DOC LG="FR">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:FR:HTML</URI_DOC>
            <URI_DOC LG="EL">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:EL:HTML</URI_DOC>
            <URI_DOC LG="IT">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:IT:HTML</URI_DOC>
            <URI_DOC LG="NL">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:NL:HTML</URI_DOC>
            <URI_DOC LG="PT">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:PT:HTML</URI_DOC>
            <URI_DOC LG="SV">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:SV:HTML</URI_DOC>
            <URI_DOC LG="CS">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:CS:HTML</URI_DOC>
            <URI_DOC LG="ET">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:ET:HTML</URI_DOC>
            <URI_DOC LG="HU">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:HU:HTML</URI_DOC>
            <URI_DOC LG="LT">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:LT:HTML</URI_DOC>
            <URI_DOC LG="LV">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:LV:HTML</URI_DOC>
            <URI_DOC LG="MT">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:MT:HTML</URI_DOC>
            <URI_DOC LG="PL">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:PL:HTML</URI_DOC>
            <URI_DOC LG="SK">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:SK:HTML</URI_DOC>
            <URI_DOC LG="SL">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:SL:HTML</URI_DOC>
            <URI_DOC LG="GA">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:GA:HTML</URI_DOC>
            <URI_DOC LG="BG">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:BG:HTML</URI_DOC>
            <URI_DOC LG="RO">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:RO:HTML</URI_DOC>
            <URI_DOC LG="HR">http://ted.europa.eu/udl?uri=TED:NOTICE:019945-2018:TEXT:HR:HTML</URI_DOC>
         </URI_LIST>
         <LG_ORIG>EN</LG_ORIG>
         <ISO_COUNTRY VALUE="UK"/>
         <IA_URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</IA_URL_GENERAL>
         <ORIGINAL_CPV CODE="73210000">Research consultancy services</ORIGINAL_CPV>
         <ORIGINAL_CPV CODE="73000000">Research and development services and related consultancy services</ORIGINAL_CPV>
         <n2016:PERFORMANCE_NUTS CODE="UKI4">Inner London – East</n2016:PERFORMANCE_NUTS>
         <n2016:CA_CE_NUTS CODE="UKI4">Inner London – East</n2016:CA_CE_NUTS>
         <REF_NOTICE>
            <NO_DOC_OJS>2017/S 240-497343</NO_DOC_OJS>
         </REF_NOTICE>
      </NOTICE_DATA>
      <CODIF_DATA>
         <DS_DATE_DISPATCH>20180112</DS_DATE_DISPATCH>
         <DT_DATE_FOR_SUBMISSION>20180206 12:00</DT_DATE_FOR_SUBMISSION>
         <AA_AUTHORITY_TYPE CODE="5">European Institution/Agency or International Organisation</AA_AUTHORITY_TYPE>
         <TD_DOCUMENT_TYPE CODE="2">Additional information</TD_DOCUMENT_TYPE>
         <NC_CONTRACT_NATURE CODE="4">Services</NC_CONTRACT_NATURE>
         <PR_PROC CODE="1">Open procedure</PR_PROC>
         <RP_REGULATION CODE="3">European Institution/Agency or International Organisation</RP_REGULATION>
         <TY_TYPE_BID CODE="1">Submission for all lots</TY_TYPE_BID>
         <AC_AWARD_CRIT CODE="2">The most economic tender</AC_AWARD_CRIT>
         <MA_MAIN_ACTIVITIES CODE="S">General public services</MA_MAIN_ACTIVITIES>
         <HEADING>AGC14</HEADING>
         <INITIATOR>AG</INITIATOR>
      </CODIF_DATA>
   </CODED_DATA_SECTION>
   <TRANSLATION_SECTION>
      <ML_TITLES>
         <ML_TI_DOC LG="DA">
            <TI_CY>Forenede Kongerige, Det</TI_CY>
            <TI_TOWN>London</TI_TOWN>
            <TI_TEXT>
               <P>Virknings- og sikkerhedsundersøgelser om lægemidler.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="DE">
            <TI_CY>das Vereinigte Königreich</TI_CY>
            <TI_TOWN>London</TI_TOWN>
            <TI_TEXT>
               <P>Wirksamkeits- und Sicherheitsstudien zu Arzneimitteln</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EN">
            <TI_CY>United Kingdom</TI_CY>
            <TI_TOWN>London</TI_TOWN>
            <TI_TEXT>
               <P>Efficacy and Safety Studies on Medicines</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ES">
            <TI_CY>Reino Unido</TI_CY>
            <TI_TOWN>Londres</TI_TOWN>
            <TI_TEXT>
               <P>Estudios de eficacia y seguridad de medicamentos.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FI">
            <TI_CY>Yhdistynyt kuningaskunta</TI_CY>
            <TI_TOWN>Lontoo</TI_TOWN>
            <TI_TEXT>
               <P>Lääkkeiden tehokkuutta ja turvallisuutta koskevat tutkimukset</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="FR">
            <TI_CY>Royaume-Uni</TI_CY>
            <TI_TOWN>Londres</TI_TOWN>
            <TI_TEXT>
               <P>Études sur l’efficacité et la sécurité des médicaments</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="EL">
            <TI_CY>Ηνωμένο Βασίλειο</TI_CY>
            <TI_TOWN>Λονδίνο</TI_TOWN>
            <TI_TEXT>
               <P>Μελέτες αποτελεσματικότητας και ασφάλειας φαρμάκων</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="IT">
            <TI_CY>Regno Unito</TI_CY>
            <TI_TOWN>Londra</TI_TOWN>
            <TI_TEXT>
               <P>Studi sull'efficacia e la sicurezza dei farmaci.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="NL">
            <TI_CY>Verenigd Koninkrijk</TI_CY>
            <TI_TOWN>Londen</TI_TOWN>
            <TI_TEXT>
               <P>Onderzoeken betreffende de doeltreffendheid en veiligheid van geneesmiddelen.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PT">
            <TI_CY>Reino Unido</TI_CY>
            <TI_TOWN>Londres</TI_TOWN>
            <TI_TEXT>
               <P>Estudos no domínio da eficácia e segurança sobre medicamentos.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SV">
            <TI_CY>Förenade kungariket</TI_CY>
            <TI_TOWN>London</TI_TOWN>
            <TI_TEXT>
               <P>Studier avseende läkemedels effektivitet och säkerhet.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="CS">
            <TI_CY>Spojené království/Velká Británie</TI_CY>
            <TI_TOWN>Londýn</TI_TOWN>
            <TI_TEXT>
               <P>Studie účinnosti a bezpečnosti léčivých přípravků</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="ET">
            <TI_CY>Suurbritannia / Ühendkuningriik</TI_CY>
            <TI_TOWN>London</TI_TOWN>
            <TI_TEXT>
               <P>Ravimite tõhususe ja ohutuse uuringud</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HU">
            <TI_CY>Egyesült Királyság</TI_CY>
            <TI_TOWN>London</TI_TOWN>
            <TI_TEXT>
               <P>Gyógyszerekre vonatkozó hatékonysági és biztonságossági vizsgálatok</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LT">
            <TI_CY>Jungtinė Karalystė, Didžioji Britanija</TI_CY>
            <TI_TOWN>Londonas</TI_TOWN>
            <TI_TEXT>
               <P>Vaistų veiksmingumo ir saugumo tyrimai.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="LV">
            <TI_CY>Apvienotā Karaliste</TI_CY>
            <TI_TOWN>Londona</TI_TOWN>
            <TI_TEXT>
               <P>Zāļu efektivitātes un drošuma pētījumi.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="MT">
            <TI_CY>Ir-Renju Unit</TI_CY>
            <TI_TOWN>Londra</TI_TOWN>
            <TI_TEXT>
               <P>Studji ta' effikaċja u sikurezza dwar il-mediċini</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="PL">
            <TI_CY>Zjednoczone Królestwo</TI_CY>
            <TI_TOWN>Londyn</TI_TOWN>
            <TI_TEXT>
               <P>Badanie skuteczności i bezpieczeństwa leków</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SK">
            <TI_CY>Spojené kráľovstvo</TI_CY>
            <TI_TOWN>Londýn</TI_TOWN>
            <TI_TEXT>
               <P>Štúdie o účinnosti a bezpečnosti liekov.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="SL">
            <TI_CY>Združeno kraljestvo</TI_CY>
            <TI_TOWN>London</TI_TOWN>
            <TI_TEXT>
               <P>Raziskave zdravil glede učinkovitosti in varnosti.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="GA">
            <TI_CY>Ríocht Aontaithe, an</TI_CY>
            <TI_TOWN>Londain</TI_TOWN>
            <TI_TEXT>
               <P>Staidéir éifeachtúlachta agus sábháilteachta i leith cógas leighis</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="BG">
            <TI_CY>Обединено кралство</TI_CY>
            <TI_TOWN>Лондон</TI_TOWN>
            <TI_TEXT>
               <P>Проучвания за ефикасност и безопасност на лекарствата.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="RO">
            <TI_CY>Regatul Unit</TI_CY>
            <TI_TOWN>Londra</TI_TOWN>
            <TI_TEXT>
               <P>Studii de eficacitate și siguranță privind medicamentele.</P>
            </TI_TEXT>
         </ML_TI_DOC>
         <ML_TI_DOC LG="HR">
            <TI_CY>Ujedinjena Kraljevina</TI_CY>
            <TI_TOWN>London</TI_TOWN>
            <TI_TEXT>
               <P>Studije djelotvornosti i sigurnosti lijekova.</P>
            </TI_TEXT>
         </ML_TI_DOC>
      </ML_TITLES>
      <ML_AA_NAMES>
         <AA_NAME LG="DA">Det Europæiske Lægemiddelagentur</AA_NAME>
         <AA_NAME LG="DE">Europäische Arzneimittel-Agentur</AA_NAME>
         <AA_NAME LG="EN">European Medicines Agency</AA_NAME>
         <AA_NAME LG="ES">Agencia Europea de Medicamentos</AA_NAME>
         <AA_NAME LG="FI">Euroopan lääkevirasto</AA_NAME>
         <AA_NAME LG="FR">Agence européenne des médicaments</AA_NAME>
         <AA_NAME LG="EL">Ευρωπαϊκός Οργανισμός Φαρμάκων</AA_NAME>
         <AA_NAME LG="IT">Agenzia europea per i medicinali</AA_NAME>
         <AA_NAME LG="NL">Europees Geneesmiddelenbureau</AA_NAME>
         <AA_NAME LG="PT">Agência Europeia de Medicamentos</AA_NAME>
         <AA_NAME LG="SV">Europeiska läkemedelsmyndigheten</AA_NAME>
         <AA_NAME LG="CS">Evropská agentura pro léčivé přípravky</AA_NAME>
         <AA_NAME LG="ET">Euroopa Ravimiamet</AA_NAME>
         <AA_NAME LG="HU">Európai Gyógyszerügynökség</AA_NAME>
         <AA_NAME LG="LT">Europos vaistų agentūra</AA_NAME>
         <AA_NAME LG="LV">Eiropas Zāļu aģentūra</AA_NAME>
         <AA_NAME LG="MT">L-Aġenzija Ewropea għall-Mediċini</AA_NAME>
         <AA_NAME LG="PL">Europejska Agencja Leków</AA_NAME>
         <AA_NAME LG="SK">Európska agentúra pre lieky</AA_NAME>
         <AA_NAME LG="SL">Evropska agencija za zdravila</AA_NAME>
         <AA_NAME LG="GA">An Ghníomhaireacht Leigheasra Eorpach</AA_NAME>
         <AA_NAME LG="BG">Европейска агенция по лекарствата</AA_NAME>
         <AA_NAME LG="RO">Agenția Europeană pentru Medicamente</AA_NAME>
         <AA_NAME LG="HR">Europska agencija za lijekove</AA_NAME>
      </ML_AA_NAMES>
   </TRANSLATION_SECTION>
   <FORM_SECTION>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="DA">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Det Europæiske Lægemiddelagentur</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Virknings- og sikkerhedsundersøgelser om lægemidler.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Undersøgelser i effektivitet og farmakoepidemiologi efter godkendelse med henblik på at generere data og oplysninger til støtte for den lovgivningsmæssige beslutningsproces. Forskningen vil også fokusere på effektiviteten af trufne lovgivningsmæssige foranstaltninger og indvirkningen af relevant lovgivning. Omfanget af emner, der skal undersøges, er begrænset til områder, der er af stor relevans for den offentlige sundhed, og som har indvirkning på Europa. Anvendelsesområdet i henseende til finansiering dækker både nationalt og centralt godkendte produkter, herunder vacciner. Resultaterne fra denne forskning vil efterfølgende blive vurderet af det ansvarlige agenturudvalg med hensyn til behovet for regulatoriske handlinger, og yderligere forskning kan efterfølgende blive udført for at måle effektiviteten af de regulatoriske handlinger, der blev udført.</P>
               <P>Forskningen kan vedrøre fire forskellige partier, med maksimalt fem rammeaftaler for partierne 1, 2 og 3 og maksimalt 8 rammeaftaler for parti 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="DE">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europäische Arzneimittel-Agentur</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Wirksamkeits- und Sicherheitsstudien zu Arzneimitteln</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Wirksamkeits- und Pharmakoepidemiologie-Studien nach der Zulassung zur Erzeugung von Daten und Informationen zur Unterstützung der regulatorischen Entscheidungsfindung. Bei der Forschung kann auch ein Schwerpunkt auf die Wirksamkeit der getroffenen regulatorischen Maßnahmen und auf die Auswirkungen der einschlägigen Rechtsvorschriften gelegt werden. Die Bandbreite der Forschungsthemen beschränkt sich auf solche mit hoher Relevanz für die öffentliche Gesundheit und Auswirkungen für Europa. In den Geltungsbereich der Förderung fallen sowohl national als auch zentral zugelassene Produkte, einschließlich Impfstoffe. Die Ergebnisse dieser Forschung werden anschließend vom verantwortlichen Gremium der Agentur hinsichtlich der Notwendigkeit von Regulierungsmaßnahmen bewertet, und es können anschließend weitere Untersuchungen durchgeführt werden, um die Wirksamkeit gesetzgeberischer Maßnahmen zu messen.</P>
               <P>Die Forschung kann sich auf vier verschiedene Lose beziehen, mit maximal fünf Rahmenverträgen für die Lose 1, 2 und 3 und maximal 8 Rahmenverträgen für Los 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="ORIGINAL" FORM="F14" LG="EN">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>European Medicines Agency</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Efficacy and Safety Studies on Medicines</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Post-authorisation effectiveness and pharmacoepidemiology studies to generate data and information to support regulatory decision-making. Research may also focus on the effectiveness of regulatory measures taken and on the impact of relevant legislation. The range of research topics is limited to those with high public health relevance and with an European impact. The scope of the funding covers both nationally and centrally authorised products, including vaccines. The results obtained from this research will subsequently be assessed by the responsible Agency Committee regarding the need for regulatory action and further research may subsequently also be conducted to measure the effectiveness of regulatory actions taken.</P>
               <P>The research may concern 4 different lots, with a maximum of 5 framework contracts for lots 1, 2 and 3 and a maximum of 8 framework contracts for lot 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="ES">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Agencia Europea de Medicamentos</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Estudios de eficacia y seguridad de medicamentos.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Estudios farmacoepidemiológicos y de eficacia posteriores a la autorización para generar datos e información que apoyen la adopción de decisiones reguladoras. La investigación también se podrá centrar en la eficacia de las medidas reguladoras tomadas y en las repercusiones de la legislación pertinente. El ámbito de los temas de investigación se limita a aquellos temas que sean de gran relevancia para la salud pública y con impacto a nivel europeo. El ámbito de la financiación cubre los productos autorizados tanto centralmente como nacionalmente, incluidas las vacunas. El comité de la agencia responsable evaluará los resultados obtenidos en esta investigación para valorar la necesidad de acción reguladora, y también se podrán llevar a cabo más investigaciones para determinar la eficacia de las acciones reguladoras tomadas.</P>
               <P>La investigación puede incluir 4 lotes distintos, con un máximo de 5 contratos marco para los lotes 1, 2 y 3, y un máximo de 8 contratos marco para el lote 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="FI">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Euroopan lääkevirasto</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Lääkkeiden tehokkuutta ja turvallisuutta koskevat tutkimukset</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Sopimuksen kohteena on myyntiluvan myöntämisen jälkeistä tehokkuutta ja farmakoepidemiologiaa koskeva tutkimus sellaisten tietojen tuottamiseksi, joiden avulla tuetaan sääntelyyn liittyvää päätöksentekoa. Tutkimuksessa voidaan keskittyä myös toteutettujen sääntelytoimenpiteiden tehokkuuteen ja asiaankuuluvan lainsäädännön vaikutuksiin. Tutkimusaiheet rajoitetaan koskemaan kansanterveyden kannalta erittäin tärkeitä kysymyksiä, joilla on vaikutuksia Euroopassa. Rahoitus kattaa sekä kansallisesti että keskitetysti hyväksytyt valmisteet, myös rokotteet. Tämän jälkeen asiasta vastaava virastokomitea arvioi tutkimuksesta saatuja tietoja sääntelytoimien tarpeellisuuden kannalta, ja myös täydentäviä tutkimuksia voidaan suorittaa suoritettujen sääntelytoimien tehokkuuden mittaamiseksi.</P>
               <P>Tutkimus voi koskea neljää eri erää, ja puitesopimuksia tehdään enintään 4 erien 1, 2 ja 3 osalta ja enintään 8 erän 4 osalta.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="FR">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Agence européenne des médicaments</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Études sur l’efficacité et la sécurité des médicaments</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Efficacité post-autorisation et études pharmaco-épidémiologiques afin de générer des données et des informations pour soutenir la prise de décision réglementaire. La recherche pourra également se focaliser sur l’efficacité des mesures réglementaires prises et sur l’impact de la législation applicable. Les sujets d'étude sont limités à ceux qui présentent un intérêt élevé pour la santé publique et qui ont un impact à l'échelle européenne. Le champ d’application du fond couvre les produits autorisés au niveau national ainsi qu’au niveau central, y compris les vaccins. Les résultats de cette recherche seront par la suite évalués par le comité de l’agence compétente quant à la nécessité d’actions réglementaires et d’autres recherches pourront également être menées par la suite afin d’évaluer l’efficacité des actions réglementaires prises.</P>
               <P>La recherche pourra porter sur quatre lots différents, avec un maximum de cinq contrats-cadres pour les lots 1, 2 et 3 et un maximum de 8 contrats-cadres pour le lot 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="EL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Ευρωπαϊκός Οργανισμός Φαρμάκων</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Μελέτες αποτελεσματικότητας και ασφάλειας φαρμάκων</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Μετεγκριτικές μελέτες αποτελεσματικότητας και φαρμακοεπιδημιολογίας για την παραγωγή δεδομένων και πληροφοριών σχετικά με την υποστήριξη της λήψης αποφάσεων σε ρυθμιστικά θέματα. Η έρευνα μπορεί επίσης να επικεντρωθεί στην αποτελεσματικότητα των ληφθέντων ρυθμιστικών μέτρων και στον αντίκτυπο της σχετικής νομοθεσίας. Το εύρος θεμάτων έρευνας περιορίζεται σε αυτά που σχετίζονται σε μεγάλο βαθμό με τη δημόσια υγεία και έχουν αντίκτυπο σε ευρωπαϊκό επίπεδο. Το εύρος της χρηματοδότησης καλύπτει τόσο εθνικά όσο και προϊόντα με άδεια κυκλοφορίας μέσω κεντρικής διαδικασίας, συμπεριλαμβανομένων των εμβολίων. Τα αποτελέσματα που θα προκύψουν από την έρευνα αυτή θα αξιολογηθούν εκ των υστέρων από την αρμόδια επιτροπή του οργανισμού σχετικά με την ανάγκη ρυθμιστικής δράσης και, στη συνέχεια, μπορεί να διεξαχθεί περαιτέρω έρευνα για τη μέτρηση της αποτελεσματικότητας των ληφθέντων ρυθμιστικών δράσεων.</P>
               <P>Η έρευνα μπορεί να αφορά τέσσερις διαφορετικές παρτίδες, με πέντε συμβάσεις-πλαίσια κατ΄ ανώτατο όριο για τις παρτίδες 1, 2 και 3 και 8 συμβάσεις-πλαίσια κατ΄ ανώτατο όριο για την παρτίδα 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="IT">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Agenzia europea per i medicinali</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studi sull'efficacia e la sicurezza dei farmaci.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Studi sulla farmacoepidemiologia e l'efficacia post-autorizzazione allo scopo di produrre dati e informazioni onde sostenere il processo decisionale regolamentare. La ricerca può anche riguardare l'efficacia delle misure regolamentari adottate e l'impatto della legislazione pertinente. La gamma delle tematiche di ricerca sarà limitata a quelle con elevata rilevanza sulla sanità pubblica e con un impatto europeo. Lo scopo del finanziamento riguarda prodotti autorizzati a livello nazionale e centrale, compresi i vaccini. I risultati ottenuti dalla ricerca in oggetto verranno successivamente valutati dalla commissione dell'agenzia responsabile in merito alla necessità di un'azione normativa e potranno essere successivamente condotte ulteriori ricerche per misurare l'efficacia delle azioni normative intraprese.</P>
               <P>La ricerca potrà interessare 4 lotti diversi, con un massimo di 5 contratti quadro per i lotti 1, 2 e 3 e un massimo di 8 contratti quadro per il lotto 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="NL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europees Geneesmiddelenbureau</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Onderzoeken betreffende de doeltreffendheid en veiligheid van geneesmiddelen.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Doeltreffendheids- en farmaco-epidemiologisch onderzoeken (na toelating) voor het genereren van gegevens en informatie ter ondersteuning van besluitvorming inzake regulering. Het onderzoek kan zich tevens toespitsen op de doeltreffendheid van de regulerende maatregelen en de effecten van relevante wetgeving. De onderzoeksonderwerpen zijn beperkt tot deze met grote relevantie voor de volksgezondheid en met een effect in Europa. Het bereik van de financiering dekt zowel nationaal als centraal vergunde producten, met inbegrip van vaccins. De resultaten die door dit onderzoek worden bekomen, zullen vervolgens worden beoordeeld door de verantwoordelijke commissie van het bureau met betrekking tot de behoefte aan regelgevende actie en daarna kan ook verder onderzoek worden uitgevoerd om de doeltreffendheid van de ondernomen regelgevende acties te meten.</P>
               <P>Het onderzoek kan betrekking hebben op 4 verschillende percelen, met maximaal 5 raamovereenkomsten voor percelen 1, 2 en 3 en maximaal 8 raamovereenkomsten voor perceel 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="PT">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Agência Europeia de Medicamentos</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Estudos no domínio da eficácia e segurança sobre medicamentos.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Investigação no domínio da farmacoepidemiologia e eficácia após autorização para geração de dados e informação de apoio na tomada de decisão regulamentar. A investigação pode ainda centrar-se na eficácia das medidas regulamentares adotadas e no impacto da legislação relevante. A abrangência dos tópicos está limitada aos que tenham uma relevância significativa para a saúde pública e um impacto europeu. O âmbito do financiamento cobre produtos autorizados a níveis nacional e central, incluindo as vacinas. Os resultados obtidos a partir desta pesquisa serão posteriormente avaliados pela comissão da agência responsável sobre a necessidade de uma ação regulamentar e também podem ser realizadas investigações adicionais para medir a eficácia das ações regulamentares tomadas.</P>
               <P>A investigação pode referir-se a 4 lotes diferentes, com um máximo de 5 contratos-quadro para os lotes 1,2 e 3 e um máximo de 8 contratos-quadro para o lote 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="SV">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europeiska läkemedelsmyndigheten</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studier avseende läkemedels effektivitet och säkerhet.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Effektivitetsforskning och farmakoepidemiologiforskning efter godkännande för försäljning i syfte att generera data och information till stöd för beslutsfattande beträffande föreskrifter. Forskningen kan även inriktas på effektiviteten av vidtagna reglerande åtgärder och på effekterna av relevant lagstiftning. Forskningsämnenas omfattning är begränsad till områden som är av stor relevans för folkhälsan och som har betydelse för Europa. Finansieringens omfattning täcker både nationellt och centralt godkända produkter, inbegripet vacciner. Resultaten från denna forskning kommer sedan att bedömas av den ansvariga kommittén avseende behovet för lagstiftningsåtgärder och vidare forskning kan också senare utföras för att mäta effektiviteten av de tagna lagstiftningsåtgärderna.</P>
               <P>Forskningen kan gälla 4 olika delar, med högst 5 ramavtal för del 1, 2 och 3 och högst 8 ramavtal för del 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="CS">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Evropská agentura pro léčivé přípravky</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studie účinnosti a bezpečnosti léčivých přípravků</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Studie zaměřená na účinnost a farmakoepidemiologii v návaznosti na schvalování léčiv s cílem získat údaje a informace na podporu rozhodování v oblasti regulace. Výzkum se může zaměřit také na účinnost přijatých regulačních opatření a na dopad příslušné legislativy. Rozsah témat výzkumu se omezuje na ta s velkým významem pro veřejné zdravotnictví a s evropským dopadem. Rozsah financování zahrnuje národně i centrálně schvalované výrobky, včetně vakcín. Výsledky získané v tomto výzkumu budou následně hodnoceny odpovědným výborem agentury, co se týče potřeby regulačních opatření, a může být následně proveden další výzkum s cílem posoudit efektivitu přijatých regulačních opatření.</P>
               <P>Výzkum se může týkat čtyř různých položek. Na položky č. 1, 2 a 3 může být uzavřeno maximálně pět rámcových smluv a na položku č. 4 maximálně 8 rámcových smluv.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="ET">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Euroopa Ravimiamet</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Ravimite tõhususe ja ohutuse uuringud</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Loasaamisjärgne mõjusus ja farmako-epidemioloogilised uuringud regulatiivsete otsuste langetamise toetamiseks mõeldud andmete ja teabe koostamiseks. Uuringutes võidakse keskenduda ka võetud regulatiivsete meetmete mõjususele ja asjakohaste õigusaktide mõjule. Uurimisteemade ulatus on piiratud üksnes teemadega, mis on rahvatervise jaoks väga olulised ja mille mõju avaldub Euroopa tasandil. Rahastamise ulatus hõlmab nii riikliku kui ka keskse loaga tooteid, sh vaktsiine. Uuringu tulemusi regulatiivmeetmete vajaduse seisukohast hindab seejärel ameti vastutav komisjon ning samuti võidakse teostada täiendavaid uuringuid, et mõõta võetud regulatiivmeetmete tõhusust.</P>
               <P>Uuringud võivad puudutada 4 erinevat osa, kusjuures 1., 2. ja 3. osa kohta sõlmitakse maksimaalselt 5 raamlepingut ning 4. osa kohta maksimaalselt 8 raamlepingut.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="HU">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Európai Gyógyszerügynökség</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Gyógyszerekre vonatkozó hatékonysági és biztonságossági vizsgálatok</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Engedélyezés utáni gyógyszerhatékonysági és farmakoepidemiológiai vizsgálatok adatok és információk előállításához a szabályozási döntéshozatal támogatása céljából. A kutatás a szabályozói intézkedések hatékonyságára és a vonatkozó jogszabályok hatására is összpontosíthat. A kutatási témák a közegészségügyi szempontból nagy jelentőségű és európai hatású témákra korlátozódnak. A finanszírozás mind a nemzetileg, mind a központilag engedélyezett termékekre, többek között a vakcinákra is kiterjed. A kutatásból származó eredményeket a későbbiekben értékelni fogja a felelős ügynökség bizottsága szabályozási intézkedés szükségességét illetően, valamint további kutatás is végezhető a későbbiekben a szabályozási intézkedések hatékonyságának felmérése céljából.</P>
               <P>A kutatás 4 különböző tételre vonatkozhat, az 1., 2. és 3. tétel esetében legfeljebb 5, a 4. tétel esetében pedig legfeljebb 8 keretszerződés megkötésével.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="LT">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europos vaistų agentūra</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Vaistų veiksmingumo ir saugumo tyrimai.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Poregistraciniai veiksmingumo ir farmakoepidemiologijos tyrimai duomenims ir informacijai surinkti siekiant remti reguliavimo sprendimų priėmimą. Moksliniais tyrimais taip pat gali būti atkreipiamas dėmesys į reguliavimo priemonių, kurių buvo imtasi, veiksmingumą ir į tinkamų teisės aktų poveikį. Tyrimų temos yra ribotos tiems, kuriems visuomenės sveikata yra itin svarbi ir kurie turi įtakos Europos mastu. Finansavimas vykdomas vaistams, įskaitant vakcinas, kurių rinkodaros leidimas išduotas taikant nacionalinę ir centralizuotą procedūrą. Šio tyrimo metu gauti rezultatai bus įvertinti atsakingo agentūros komiteto reguliavimo priemonių poreikio atžvilgiu, o vėliau galimai bus atlikti tolesni tyrimai, skirti įvertinti priimtų reguliavimo priemonių veiksmingumą.</P>
               <P>Tyrimas gali būti padalintas į keturias skirtingas dalis, skiriant ne daugiau kaip 5 preliminariąsias sutartis 1, 2 ir 3 dalims ir ne daugiau kaip 8 preliminariąsias sutartis 4 daliai.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="LV">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Eiropas Zāļu aģentūra</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Zāļu efektivitātes un drošuma pētījumi.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Pēcreģistrācijas izpēte attiecībā uz iedarbīgumu un farmakoepidemioloģiju nolūkā iegūt datus un informāciju, ko varētu izmantot reglamentējošu lēmumu pieņemšanā. Var būt jāpēta arī īstenoto reglamentējošo pasākumu iedarbīgums un attiecīgo tiesību aktu ietekme. Pētniecības tematu klāstā ir iekļauti tie temati, kas ir īpaši svarīgi sabiedrības veselībai un kam ir ietekme Eiropas mērogā. Finansējumā ir ietverti gan valstīs, gan centralizēti atļauti produkti, tostarp vakcīnas. Pētījumu rezultātus novērtēs aģentūras atbildīgā komiteja, nosakot vajadzību veikt regulatīvas darbības; var tikt veikti arī papildu pētījumi, lai apzinātu veikto regulatīvo darbību efektivitāti.</P>
               <P>Pētījumi var būt saistīti ar 4 dažādām daļām, noslēdzot ne vairāk kā 5 pamatnolīgumus par 1., 2. un 3. daļu un ne vairāk kā 8 pamatnolīgumus par 4. daļu.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="MT">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>L-Aġenzija Ewropea għall-Mediċini</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studji ta' effikaċja u sikurezza dwar il-mediċini</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Studji dwar l-effettività wara l-awtorizzazzjoni u dwar il-farmakoepidemjoloġija biex jiġu ġġenerati dejta u tagħrif għal appoġġ fit-teħid ta' deċiżjonijiet regolatorji. Ir-riċerka tista' tiffoka wkoll fuq l-effettività ta' miżuri regolatorji meħuda u fuq l-impatt ta' leġiżlazzjoni rilevanti. Ir-riċerka tista' tiffoka wkoll fuq l-effettività ta' miżuri regolatorji meħuda u fuq l-impatt ta' leġiżlazzjoni rilevanti. L-għan tal-iffinanzjar ikopri prodotti awtorizzati kemm f'livell nazzjonali kif ukoll ċentrali, inkluż vaċċini. Ir-riżultati li jinkisbu minn din ir-riċerka sussegwentement ser jiġu vvalutati mill-kumitat responsabbli tal-aġenzija rigward il-ħtieġa ta' azzjoni regolatorja u wara dan tista' ssir aktar riċerka sabiex titqies l-effettività tal-azzjonijiet regolatorji li jkunu ttieħdu.</P>
               <P>Ir-riċerka tista' tikkonċerna erba' lottijiet differenti, b'massimu ta' ħames oqfsa ta' kuntratt għal-lottijiet 1, 2 u 3, u massimu ta' 8 oqfsa ta' kuntratt għal-lott 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="PL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europejska Agencja Leków</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Badanie skuteczności i bezpieczeństwa leków</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Badanie skuteczności i farmakoepidemiologiczne po wydaniu zatwierdzenia w celu opracowania danych i informacji na potrzeby wsparcia regulacyjnego procesu decyzyjnego. Badanie może również koncentrować się na skuteczności podjętych środków regulacyjnych i wpływie odpowiednich przepisów prawa. Zakres tematyczny jest ograniczony i obejmuje jedynie zagadnienia o dużym znaczeniu dla zdrowia publicznego oraz wywierające wpływ w wymiarze europejskim. Zakres finansowania obejmuje zarówno produkty zatwierdzone na poziomie krajowym, jak i centralnym, między innymi szczepionki. Wyniki niniejszego badania zostaną następnie ocenione przez właściwą komisję agencji pod kątem konieczności podjęcia działań regulacyjnych. Następnie może zostać przeprowadzone kolejne badanie w celu oceny skuteczności podjętych działań regulacyjnych.</P>
               <P>Badanie może dotyczyć 4 różnych części, podpisanych może zostać nie więcej niż 5 umów ramowych dla części 1, 2 i 3 oraz nie więcej niż 8 umów ramowych dla części 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="SK">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Európska agentúra pre lieky</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Štúdie o účinnosti a bezpečnosti liekov.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Poregistračné farmakoepidemiologické štúdie a štúdie účinnosti s cieľom vygenerovať údaje a informácie na podporu prijímania regulačných rozhodnutí. Výskum môže byť tiež zameraný na účinnosť prijatých regulačných opatrení a na vplyv príslušných právnych predpisov. Rozsah výskumných tém je obmedzený na tie, ktoré sú veľmi významné z hľadiska verejného zdravia a ktoré majú európsky dosah. Rozsah finančných prostriedkov zahŕňa vnútroštátne, ako aj centrálne povolené lieky vrátane vakcín. Výsledky získané na základe tohto výskumu následne posúdi príslušný výbor agentúry, pokiaľ ide o potrebu regulačných opatrení, a následne sa môže vykonať ďalší výskum na hodnotenie účinnosti prijatých regulačných opatrení.</P>
               <P>Výskum sa môže týkať 4 rôznych častí s maximálne 5 rámcovými zmluvami pre časti 1, 2 a 3 a maximálne 8 rámcovými zmluvami pre časť 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="SL">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Evropska agencija za zdravila</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Raziskave zdravil glede učinkovitosti in varnosti.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Raziskave na področju učinkovitosti in farmakoepidemiologije po izdaji dovoljenja za ustvarjanje podatkov in informacij v podporo regulativnemu odločanju. Raziskave so lahko osredotočene tudi na učinkovitost sprejetih regulativnih ukrepov in učinek ustrezne zakonodaje. Obseg raziskovalnih tem je omejen na tiste z visoko pomembnostjo za javno zdravje in z evropskim učinkom. Obseg financiranja zajema nacionalno in centralno odobrena zdravila, vključno s cepivi. Rezultate, pridobljene s temi raziskavami, bo pristojni odbor agencije naknadno ocenil glede potrebe po regulativnem ukrepu, nato pa se lahko izvede tudi nadaljnje raziskave za merjenje učinkovitosti sprejetih regulativnih ukrepov.</P>
               <P>Raziskava se lahko nanaša na 4 različne serije, z največ 5 okvirnimi naročili za sklope 1, 2 in 3 ter največ 8 okvirnimi naročili za sklop 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="GA">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>An Ghníomhaireacht Leigheasra Eorpach</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Staidéir éifeachtúlachta agus sábháilteachta i leith cógas leighis</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Taighde iar-údaracháin um éifeachtacht agus um staidéir chógas-eipidéimeolaíochta chun sonraí agus faisnéis a ghiniúint chun tacú le cinnteoireacht rialála. Féadfar an taighde a dhíriú freisin ar éifeachtacht na mbeart rialála a glacadh agus ar thionchar na reachtaíochta ábhartha. Tá raon na n-ábhar taighde teoranta dóibh siúd lena mbaineann ábharthacht mhór maidir le sláinte phoiblí agus le tionchar Eorpach. Cumhdaítear le raon feidhme an chistithe idir tháirgí údaraithe go náisiúnta agus go lárnach, lena n-áirítear vacsaíní. Déanfaidh coiste na gníomhaireachta freagraí measúnú ar na torthaí a fhaightear ón taighde seo ina dhiaidh sin maidir leis an éileamh do ghníomhaíocht rialála, agus féadfar tuilleadh taighde a stiúradh ina dhiaidh sin chun éifeachtacht na gníomhaíochta rialála glactha a thomhas.</P>
               <P>Féadfar an taighde a dhéanamh i leith ceithre bheart éagsúla, le cúig chreatchonradh ar a uasmhéad i leith beart 1, 2 agus 3; agus le 8 gcreatchonradh ar a uasmhéad do bheart 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="BG">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Европейска агенция по лекарствата</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Проучвания за ефикасност и безопасност на лекарствата.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Проучвания за ефективност и фармакоепидемиология след получаване на разрешение с цел генериране на данни и информация в подкрепа на регулаторното вземане на решения. Проучването може да се концентрира също и върху ефективността на предприетите регулаторни мерки и върху въздействието на съответното законодателство. Обхватът на изследователските теми е ограничен до тези, които се са с голямо значение за общественото здравеопазване и са с европейското въздействие. Обхватът на финансирането обхваща разрешени продукти, включително ваксини, на национално и централно ниво. Получените резултати от това проучване ще бъдат впоследствие оценени от комисията на компетентната агенция относно необходимостта от регулаторни действия и впоследствие могат да бъдат проведени допълнителни проучвания за измерване на ефективността на предприетите регулаторни действия.</P>
               <P>Проучването може да се отнася до четири различни обособени позиции с максимум пет рамкови договора за обособени позиции 1, 2 и 3 и максимум 8 рамкови договора за обособена позиция 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="RO">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Agenția Europeană pentru Medicamente</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studii de eficacitate și siguranță privind medicamentele.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Studii în domeniul eficacității și al farmacoepidemiologiei ulterior autorizării pentru generarea de date și de informații pentru susținerea procesului decizional în materie de reglementare. Cercetarea se poate axa, de asemenea, pe eficacitatea măsurilor de reglementare adoptate și pe impactul legislației relevante. Gama de subiecte este limitată la cele de înaltă relevanță pentru sănătatea publică și cu impact la nivel european. Finanțarea acoperă produse autorizate atât la nivel național, cât și central, incluzând vaccinurile. Rezultatele obținute în urma acestei cercetări vor fi ulterior evaluate de comitetul competent al agenției cu privire la necesitatea unei acțiuni de reglementare și pot fi efectuate ulterior cercetări suplimentare pentru a măsura eficacitatea măsurilor de reglementare luate.</P>
               <P>Cercetarea poate viza patru loturi diferite, cu maximum cinci contracte-cadru pentru loturile 1, 2 și 3 și maximum 8 contracte-cadru pentru lotul 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
      <F14_2014 CATEGORY="TRANSLATION" FORM="F14" LG="HR">
         <CONTRACTING_BODY>
            <ADDRESS_CONTRACTING_BODY>
               <OFFICIALNAME>Europska agencija za lijekove</OFFICIALNAME>
               <ADDRESS>30 Churchill Place</ADDRESS>
               <TOWN>London</TOWN>
               <POSTAL_CODE>E14 5EU</POSTAL_CODE>
               <COUNTRY VALUE="UK"/>
               <E_MAIL>pass.tender@ema.europa.eu</E_MAIL>
               <n2016:NUTS CODE="UKI4"/>
               <URL_GENERAL>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_GENERAL>
               <URL_BUYER>http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000259.jsp&amp;mid=WC0b01ac0580029487</URL_BUYER>
            </ADDRESS_CONTRACTING_BODY>
         </CONTRACTING_BODY>
         <OBJECT_CONTRACT>
            <TITLE>
               <P>Studije djelotvornosti i sigurnosti lijekova.</P>
            </TITLE>
            <REFERENCE_NUMBER>EMA/2017/09/PE</REFERENCE_NUMBER>
            <CPV_MAIN>
               <CPV_CODE CODE="73000000"/>
            </CPV_MAIN>
            <TYPE_CONTRACT CTYPE="SERVICES"/>
            <SHORT_DESCR>
               <P>Studije djelotvornosti i farmakoepidemiološke studije nakon izdavanja odobrenja kako bi se prikupili podaci i informacije koji bi podržali regulatorno odlučivanje. Istraživanje se također može usmjeriti na učinkovitost poduzetih regulatornih mjera i na učinak relevantnog zakonodavstva. Raspon tema je ograničen na one od velike važnosti za javno zdravlje i s europskim učinkom. Opseg financiranja pokriva nacionalno i centralno odobrene proizvode, uključujući i cjepiva. Rezultate dobivene ovim istraživanjem naknadno će ocijeniti nadležni odbor agencije u pogledu potrebe za regulatornim radnjama te je moguća i naknadna provedba daljnjeg istraživanja za mjerenje učinkovitosti poduzetih regulatornih radnji.</P>
               <P>Istraživanje se može odnositi na 4 različite grupe, s maksimalno 5 okvirnih ugovora za grupe 1, 2 i 3 i maksimalno 8 okvirnih ugovora za grupu 4.</P>
            </SHORT_DESCR>
         </OBJECT_CONTRACT>
         <COMPLEMENTARY_INFO>
            <DATE_DISPATCH_NOTICE>2018-01-12</DATE_DISPATCH_NOTICE>
            <NOTICE_NUMBER_OJ>2017/S 240-497343</NOTICE_NUMBER_OJ>
         </COMPLEMENTARY_INFO>
         <CHANGES>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.2)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-02</DATE>
                  <TIME>12:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-06</DATE>
                  <TIME>12:00</TIME>
               </NEW_VALUE>
            </CHANGE>
            <CHANGE PUBLICATION="YES">
               <WHERE>
                  <SECTION>IV.2.7)</SECTION>
               </WHERE>
               <OLD_VALUE>
                  <DATE>2018-02-08</DATE>
                  <TIME>10:00</TIME>
               </OLD_VALUE>
               <NEW_VALUE>
                  <DATE>2018-02-12</DATE>
                  <TIME>10:00</TIME>
               </NEW_VALUE>
            </CHANGE>
         </CHANGES>
      </F14_2014>
   </FORM_SECTION>
</TED_EXPORT>
